Dawn Bir Biography and Net Worth

Chief Commercial Officer of Reata Pharmaceuticals

Dawn C. Bir joined Reata as Chief Commercial Officer in September 2016 to develop and oversee marketing, market access, sales, training, and commercial operations.

Prior to joining Reata, Ms. Bir most recently served as Vice President of Sales with Pharmacyclics, LLC. From February 2013 to September 2016, she built and led their first hematology national sales organization of sales representatives, division managers and regional sales directors responsible for the launch of IMBRUVICA® in the United States and Puerto Rico. From October 2011 to February 2013, Ms. Bir served as Vice President Sales & Marketing with McKesson US Pharmaceutical, SKY Pharmaceuticals and RxPak. Prior thereto, she held positions of increasing responsibility within McKesson Corporation, Genentech, Inc. and Bristol-Myers Squibb Company.

She currently serves as a member of the board of directors of Geron Corporation, a publicly traded clinical-stage pharmaceutical company. Ms. Bir holds a B.S. in Biology from Binghamton University.

What is Dawn Carter Bir's net worth?: The estimated net worth of Dawn Carter Bir is at least $6.03 million as of July 28th, 2023. Ms. Bir owns 35,010 shares of Reata Pharmaceuticals stock worth more than $6,034,324 as of April 27th. This net worth approximation does not reflect any other assets that Ms. Bir may own. Additionally, Ms. Bir receives a salary of $652,390.00 as Chief Commercial Officer at Reata Pharmaceuticals. Learn More about Dawn Carter Bir's net worth.
How old is Dawn Carter Bir?: Ms. Bir is currently 52 years old. There are 6 older executives and no younger executives at Reata Pharmaceuticals. The oldest executive at Reata Pharmaceuticals is Mr. Michael D. Wortley, Exec. VP and Chief Legal & Compliance Officer, who is 75 years old. Learn More on Dawn Carter Bir's age.
What is Dawn Carter Bir's salary?: As the Chief Commercial Officer of Reata Pharmaceuticals, Inc., Ms. Bir earns $652,390.00 per year. There are 4 executives that earn more than Ms. Bir. The highest earning executive at Reata Pharmaceuticals is Mr. J. Warren Huff, Chairman, CEO & Sec., who commands a salary of $1,110,000.00 per year. Learn More on Dawn Carter Bir's salary.
How do I contact Dawn Carter Bir?: The corporate mailing address for Ms. Bir and other Reata Pharmaceuticals executives is 5320 LEGACY DRIVE, PLANO TX, 75024. Reata Pharmaceuticals can also be reached via phone at (972) 865-2219 and via email at [email protected]. Learn More on Dawn Carter Bir's contact information.
Has Dawn Carter Bir been buying or selling shares of Reata Pharmaceuticals?: Dawn Carter Bir has not been actively trading shares of Reata Pharmaceuticals during the past quarter. Most recently, Dawn Carter Bir sold 40,000 shares of the business's stock in a transaction on Friday, July 28th. The shares were sold at an average price of $164.54, for a transaction totalling $6,581,600.00. Following the completion of the sale, the insider now directly owns 35,010 shares of the company's stock, valued at $5,760,545.40. Learn More on Dawn Carter Bir's trading history.
Who are Reata Pharmaceuticals' active insiders?: Reata Pharmaceuticals' insider roster includes Bhaskar Anand (CAO), Dawn Bir (Chief Commercial Officer), Elaine Castellanos (CAO), Samina Khan (SVP), Andrea Loewen (SVP), Colin Meyer (Insider), Shamim Ruff (Director), Manmeet Soni (CFO), and Michael Wortley (Insider). Learn More on Reata Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Reata Pharmaceuticals?: During the last twelve months, insiders at the sold shares 10 times. They sold a total of 236,092 shares worth more than $31,588,041.37. The most recent insider tranaction occured on September, 14th when SVP Andrea Loewen sold 3,175 shares worth more than $546,195.25. Insiders at Reata Pharmaceuticals own 26.8% of the company. Learn More about insider trades at Reata Pharmaceuticals.
Information on this page was last updated on 9/14/2023.

Dawn Carter Bir Insider Trading History at Reata Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/28/2023	Sell	40,000	$164.54	$6,581,600.00	35,010
3/6/2023	Sell	54,954	$89.56	$4,921,680.24	41,925
3/3/2023	Sell	2,166	$88.25	$191,149.50	48,509

Dawn Carter Bir Buying and Selling Activity at Reata Pharmaceuticals

Reata Pharmaceuticals Company Overview

Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone to treat Friedreich's ataxia; and conduct various form of CKD, such as, type 1 and type 2 diabetic CKD, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and bardoxolone for the treatment of autosomal dominant polycystic kidney disease. In addition, the company has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Today's Range

Now: $172.36

$172.32

$172.46

50 Day Range

MA: $171.30

$168.70

$172.36

2 Week Range

Now: $172.36

$21.83

$172.46

Volume

1,988,500 shs

Average Volume

1,091,032 shs

Market Capitalization

$6.58 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

Dawn Bir Biography and Net Worth

What is Dawn Carter Bir's net worth?

How old is Dawn Carter Bir?

What is Dawn Carter Bir's salary?

How do I contact Dawn Carter Bir?

Has Dawn Carter Bir been buying or selling shares of Reata Pharmaceuticals?

Who are Reata Pharmaceuticals' active insiders?

Are insiders buying or selling shares of Reata Pharmaceuticals?